TICKERNERD
Menu
CVSCVSHealthcare · Healthcare Plans

CVS Stock Forecast: CVS Health Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$93
−0.68% on the day

The 27 Wall Street analysts covering CVS Health Corp. hold a median 12-month price target of $116 — +24.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$119.0B
Ticker Nerd rank
87 / 100
Median analyst target
$116
Analysts covering
27
Total return, dividends reinvested
1W
−4.3%
1M
−15.4%
YTD
+19.9%
1Y
+34.3%
From 52W high
−15.4%
From 52W low
+36.5%
$68
$110
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CVS Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
95
Issuance
85
Revisions
84
Momentum
82
Growth
78
Value
75
Accruals
74
Quality
25
Size
2

Volatility (95): The share price has been relatively steady.

Quality (25): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26CVSHigh $148Median $116Low $103

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says27 analysts
24 Buy3 Hold0 Sell
Low $103Median $116High $148

The green dot is the last close — the median target sits +24.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
19 Aug 2026Argus ResearchMaintainsBuy$104 → $114
12 Aug 2026JP MorganMaintainsOverweight$111 → $118
6 Aug 2026BarclaysMaintainsOverweight—
6 Aug 2026BarclaysMaintainsOverweight$106 → $108
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026Evercore ISI GroupMaintainsOutperform$130 → $125
6 Aug 2026UBSMaintainsBuy—
6 Aug 2026UBSMaintainsBuy$122 → $126
25 July 2026UBSMaintainsBuy—
24 July 2026UBSMaintainsBuy$115 → $122
14 July 2026Truist SecuritiesMaintainsBuy—
14 July 2026Truist SecuritiesMaintainsBuy$108 → $118
13 July 2026Wells FargoMaintainsOverweight—
13 July 2026Wells FargoMaintainsOverweight$103 → $123
9 July 2026RBC CapitalMaintainsOutperform—
9 July 2026RBC CapitalMaintainsOutperform$107 → $113
7 July 2026Cantor FitzgeraldMaintainsOverweight—
7 July 2026Cantor FitzgeraldMaintainsOverweight$100 → $110
23 June 2026B of A SecuritiesMaintainsBuy—
8 June 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.6%
Analysts raising
13
Analysts cutting
1
Fundamentals

CVS Health Corp. (CVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.5×

Cheaper than 32% of US stocks

Price / sales
0.3×

Cheaper than 90% of US stocks

Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
10.9×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
7.1%

Higher than 44% of US stocks

Earnings growth (YoY)
191.8%

Higher than 90% of US stocks

Gross margin
14.8%

Higher than 14% of US stocks

Operating margin
3.9%

Higher than 52% of US stocks

Net margin
1.2%

Higher than 50% of US stocks

Returns & dividend
Return on equity
6.2%

Higher than 55% of US stocks

Return on assets
3.0%

Higher than 65% of US stocks

Dividend yield
2.9%

Higher than 61% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
CVSCVS Health Corp.$119.0B
87
ELVElevance Health, Inc.$89.0B
66
CIThe Cigna Group$73.3B
70
HUMHumana, Inc.$45.6B
45
UNHUnitedHealth Group, Inc.$353.4B
75
CNCCentene Corp.$32.0B
93
MOHMolina Healthcare, Inc.$10.3B
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CVS Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVS news & analysis

CVS Health Stock Is Beating the Market in 2026. Here's Why Wall Street Thinks It Can Soar Another 22%.

The Motley Fool · 22 Aug 2026positive

The Motley Fool reports that CVS Health stock has outperformed the broader market in 2026, citing strength added to the company's fundamentals. The coverage notes that CVS has recently beaten analyst profitability estimates.

Why it matters — The news shows improving financial performance for CVS, as it has exceeded analyst profit expectations and outperformed the wider market so far this year.

CVS Health Announces Board Changes

PRNewsWire · 17 Aug 2026neutral

CVS Health announced that Teresa Heitsenrether will join its Board of Directors, bringing over forty years of operating experience in data, analytics, and technology, while Larry Robbins will depart the Board after two years at the company.

Why it matters — Board composition changes, including the addition of a director with extensive data and technology experience, are relevant to CVS watchers monitoring the company's governance and strategic direction.

Is CVS Stock a Buy as Earnings Improve but Key Risks Remain Elevated?

Zacks Investment Research · 17 Aug 2026neutral

CVS Health enters the second half of 2026 with stronger earnings and gains at its Aetna unit, according to Zacks Investment Research. However, elevated medical costs and risks at its Caremark business continue to cloud the recovery outlook.

Why it matters — CVS watchers would care because the report highlights both improving earnings momentum and the ongoing cost and Caremark risks that could affect the company's recovery.

CVS' Q2 EPS Gains From Improved Health Care Benefits Profitability

Zacks Investment Research · 17 Aug 2026positive

CVS Health reported a more than 40% jump in second-quarter EPS, driven by improved profitability in its Health Care Benefits segment. This led the company to significantly raise its 2026 adjusted operating income outlook.

Why it matters — A CVS watcher would care because stronger Health Care Benefits profitability and a major upward revision to 2026 operating income guidance point to improving core business performance.

Can CVS Sustain Its 2026 Recovery After Raising Earnings Guidance?

Zacks Investment Research · 14 Aug 2026neutral

CVS Health raised its 2026 earnings guidance, driven by stronger profits from its Aetna segment, though the recovery faces risks from medical costs and changes to pharmacy-benefit management.

Why it matters — A CVS watcher would care because the guidance raise signals improving momentum, but persistent cost pressures and PBM industry changes could threaten the sustainability of the turnaround.

FAQ

Frequently asked questions about CVS stock

What is the CVS stock price forecast for 2026-2027?

The 27 Wall Street analysts covering CVS Health Corp. have a median 12-month price target of $116, with estimates ranging from $103 to $148. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVS stock a buy right now?

Of the 27 analysts covering CVS Health Corp., 24 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CVS Health Corp. 87 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVS?

As at 22 Aug 2026, CVS Health Corp. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).

Will CVS stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +24.7% from the last close, and Ticker Nerd's factor model ranks CVS Health Corp. 87 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVS stock forecast for 2030?

No analyst covering CVS Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $148 over the next 12 months.

How has CVS stock performed over the past year?

CVS Health Corp. returned +34.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CVS Health Corp. do?

CVS Health Corporation is a diversified healthcare company that provides health solutions across insurance, pharmacy, and care delivery. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, serving individuals, employers, and other healthcare customers.

What is the latest news on CVS?

The most recent item we track (The Motley Fool, 22 Aug 2026): "CVS Health Stock Is Beating the Market in 2026. Here's Why Wall Street Thinks It Can Soar Another 22%.". The Motley Fool reports that CVS Health stock has outperformed the broader market in 2026, citing strength added to the company's fundamentals. The coverage notes that CVS has recently beaten analyst profitability estimates.

Company

About CVS Health Corp.

CVS Health Corporation is a diversified healthcare company that provides health solutions across insurance, pharmacy, and care delivery. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, serving individuals, employers, and other healthcare customers. Its businesses include health insurance products, pharmacy benefit management, retail prescription dispensing, and a broad range of health services delivered in clinics, virtually, and in the home. CVS Health also offers wellness products, vaccination services, and related pharmacy support through its nationwide network. Based in Woonsocket, Rhode Island, CVS Health plays a significant role in connecting insurance, pharmacy access, and care delivery within the U.S. healthcare system.

CEO Mr. J. David Joyner CEBS · 219,000 employees · United States · https://www.cvshealth.com